Dr. Angeles Alvarez Secord joined the Duke faculty in 2001. She is the director of Gynecologic Oncology Clinical Trials, the associate director of Clinical Research, Gynecology Oncology, and the principal investigator for the NRG Oncology cooperative group.

Dr. Secord’s research interests include development of novel therapeutics and biomarkers in gynecologic cancer, and innovative clinical trial designs. She leads several clinical trials at Duke for patients with ovarian, uterine and cervical cancer. 

Read more about DCI Clinical Trials

In addition, she started the Endometrial Cancer Molecularly Targeted Therapy Consortium (ECMT2) in 2019 and leads an annual community outreach event, She Dunks on Cancer Educational Symposium, to support patients with uterine cancers. The original nine-member ECMT2 consortium now includes over 20 sites and 4,000 patients. 

Read more about ECMT2 

Read more about She Dunks on Cancer

Banner photo credit: NCI

Recent Publications:

Advancing physician-scientist career development in obstetrics and gynecology: Forty years of the American Association of Obstetricians and Gynecologists Foundation Scholar Program.

Journal Article Am J Obstet Gynecol · July 23, 2025 Full textLink to itemCite

Expanding the workforce of clinical trial investigators committed to gynecologic cancer research: the GOG Foundation, Inc's Scholar Career Development Award and New Investigator Program.

Journal Article International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · June 2025ObjectiveTraining and supporting early-career investigators are essential for developing a resilient and competent clinical research workforce in gynecologic oncology. To address persistent gaps in mentorship, protected time, funding, and leadersh ...Full textCite

Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.

Journal Article Int J Gynecol Cancer · May 2025OBJECTIVE: Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought to confirm the proportion of patients with at least 1 actionable a ...Full textLink to itemCite

A new vision for women's health research at the National Institutes of Health from the National Academies of Sciences, Engineering, and Medicine's Consensus Report: potential impact for gynecologic cancer care and research.

Journal Article Int J Gynecol Cancer · April 2025Full textLink to itemCite

The efficacy and safety of mirvetuximab soravtansine in FRα-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial.

Journal Article Ann Oncol · March 2025BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class, folate receptor alpha (FRα)-targeting antibody-drug conjugate with United States Food and Drug Administration approval for FRα-positive platinum-resistant ovarian cancer. PICCOLO is a p ...Full textLink to itemCite

Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.

Journal Article Gynecol Oncol · March 2025BACKGROUND: This study evaluated whether patients with epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (OC) who are immediately re-treated with bevacizumab derive benefit after disease progression on a bevacizumab-containing regimen. M ...Full textLink to itemCite

Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.

Journal Article Gynecol Oncol · February 2025PURPOSE: Determine if molecular classification using mismatch repair (MMR) and p53 protein expression predicts recurrence-free survival (RFS) and overall survival (OS) in endometrial cancer (EC) patients treated with chemotherapy and radiation (CRT) versus ...Full textLink to itemCite

Complete list of publications